{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:30:39Z","timestamp":1789824639579,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00059-019-4792-9","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T08:22:57Z","timestamp":1551946977000},"page":"203-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Heart failure and diabetes: management and open issues","Herzinsuffizienz und Diabetes mellitus: Behandlung und offene Fragen"],"prefix":"10.1007","volume":"44","author":[{"given":"K.","family":"Sch\u00fctt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"4792_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1161\/CIRCHEARTFAILURE.110.952556","volume":"4","author":"D Aguilar","year":"2011","unstructured":"Aguilar D, Chan W, Bozkurt B et\u00a0al (2011) Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 4:53\u201358","journal-title":"Circ Heart Fail"},{"key":"4792_CR2","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1161\/01.CIR.0000142047.28024.F2","volume":"110","author":"D Aguilar","year":"2004","unstructured":"Aguilar D, Solomon SD, Kober L et al (2004) Newly diagnosed and previously known diabetes mellitus and 1\u2011year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110:1572\u20131578","journal-title":"Circulation"},{"key":"4792_CR3","doi-asserted-by":"crossref","unstructured":"Anonymous (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837\u2013853","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"4792_CR4","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.jacc.2007.12.048","volume":"51","author":"H Bahrami","year":"2008","unstructured":"Bahrami H, Bluemke DA, Kronmal R et al (2008) Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J\u00a0Am Coll Cardiol 51:1775\u20131783","journal-title":"J Am Coll Cardiol"},{"key":"4792_CR5","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1161\/CIRCULATIONAHA.116.024632","volume":"135","author":"MA Cavender","year":"2017","unstructured":"Cavender MA, White WB, Jarolim P et al (2017) Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (examination of cardiovascular outcomes with Alogliptin versus standard of care). Circulation 135:1911\u20131921","journal-title":"Circulation"},{"key":"4792_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ et\u00a0al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a\u00a0randomised controlled trial. Lancet 366:1279\u20131289","journal-title":"Lancet"},{"key":"4792_CR7","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2337\/dc07-0717","volume":"30","author":"E Erdmann","year":"2007","unstructured":"Erdmann E, Charbonnel B, Wilcox RG et\u00a0al (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30:2773\u20132778","journal-title":"Diabetes Care"},{"key":"4792_CR8","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart\u00a0J 37:1526\u20131534","journal-title":"Eur Heart J"},{"key":"4792_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"Gerstein HC, Bosch J, Dagenais GR et\u00a0al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N\u00a0Engl J Med 367:319\u2013328","journal-title":"N Engl J Med"},{"key":"4792_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et\u00a0al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med 373:232\u2013242","journal-title":"N Engl J Med"},{"key":"4792_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jacc.2003.11.024","volume":"43","author":"I Gustafsson","year":"2004","unstructured":"Gustafsson I, Brendorp B, Seibaek M et al (2004) Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J\u00a0Am Coll Cardiol 43:771\u2013777","journal-title":"J Am Coll Cardiol"},{"issue":"10157","key":"4792_CR12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a\u00a0double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529","journal-title":"Lancet"},{"key":"4792_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.115.002560","author":"SL Kristensen","year":"2016","unstructured":"Kristensen SL, Preiss D, Jhund PS et al (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. \n                    https:\/\/doi.org\/10.1161\/circheartfailure.115.002560","journal-title":"Circ Heart Fail"},{"key":"4792_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1900\/RDS.2011.8.382","volume":"8","author":"M Lehrke","year":"2011","unstructured":"Lehrke M, Marx N (2011) Cardiovascular effects of incretin-based therapies. Rev Diabet Stud 8:382\u2013391","journal-title":"Rev Diabet Stud"},{"key":"4792_CR15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR Macdonald","year":"2008","unstructured":"Macdonald MR, Petrie MC, Varyani F et\u00a0al (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart\u00a0J 29:1377\u20131385","journal-title":"Eur Heart J"},{"key":"4792_CR16","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et\u00a0al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N\u00a0Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"4792_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med 375:311\u2013322","journal-title":"N Engl J Med"},{"key":"4792_CR18","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","volume":"37","author":"N Marx","year":"2016","unstructured":"Marx N, Mcguire DK (2016) Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart\u00a0J 37:3192. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw110","journal-title":"Eur Heart J"},{"key":"4792_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1479164115570301","volume":"12","author":"N Marx","year":"2015","unstructured":"Marx N, Rosenstock J, Kahn SE et\u00a0al (2015) Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(R)). Diab Vasc Dis Res 12:164\u2013174","journal-title":"Diab Vasc Dis Res"},{"key":"4792_CR20","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1161\/CIRCULATIONAHA.118.034986","volume":"138","author":"DA Mcallister","year":"2018","unstructured":"Mcallister DA, Read SH, Kerssens J et al (2018) Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation 138:2774\u20132786","journal-title":"Circulation"},{"key":"4792_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/circulationaha.118.038352","volume":"139","author":"DK Mcguire","year":"2018","unstructured":"Mcguire DK, Alexander JH, Johansen OE et\u00a0al (2018) Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 139:351. \n                    https:\/\/doi.org\/10.1161\/circulationaha.118.038352","journal-title":"Circulation"},{"key":"4792_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","volume":"1","author":"DK Mcguire","year":"2016","unstructured":"Mcguire DK, Van De Werf Armstrong FPW et\u00a0al (2016) Association between Sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a\u00a0randomized clinical trial. JAMA Cardiol 1:126\u2013135","journal-title":"JAMA Cardiol"},{"key":"4792_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et\u00a0al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"4792_CR24","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","volume":"27","author":"GA Nichols","year":"2004","unstructured":"Nichols GA, Gullion CM, Koro CE et\u00a0al (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879\u20131884","journal-title":"Diabetes Care"},{"key":"4792_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et\u00a0al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891\u2013975","journal-title":"Eur J Heart Fail"},{"key":"4792_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Perkovic V, Johansen OE et\u00a0al (2018) Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. \n                    https:\/\/doi.org\/10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"4792_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"Rubler S, Dlugash J, Yuceoglu YZ et\u00a0al (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595\u2013602","journal-title":"Am J Cardiol"},{"key":"4792_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et\u00a0al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N\u00a0Engl J Med 369:1317\u20131326","journal-title":"N Engl J Med"},{"key":"4792_CR29","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:1579\u20131588","journal-title":"Circulation"},{"key":"4792_CR30","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1007\/s00125-018-4678-z","volume":"61","author":"C Wanner","year":"2018","unstructured":"Wanner C, Marx N (2018) SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 61:2134\u20132139","journal-title":"Diabetologia"},{"key":"4792_CR31","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et\u00a0al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N\u00a0Engl J Med 369:1327\u20131335","journal-title":"N Engl J Med"},{"issue":"4","key":"4792_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et\u00a0al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"key":"4792_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32590-x","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2018) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a\u00a0systematic review and meta-analysis of cardiovascular outcome trials. Lancet. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(18)32590-x","journal-title":"Lancet"},{"key":"4792_CR34","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et\u00a0al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N\u00a0Engl J Med 373:2117","journal-title":"N Engl J Med"},{"issue":"9982","key":"4792_CR35","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a\u00a0multicentre, randomised, double-blind trial. Lancet 385(9982):2067\u20132076","journal-title":"Lancet"},{"issue":"23","key":"4792_CR36","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et\u00a0al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N\u00a0Engl J Med 373(23):2247\u20132257","journal-title":"N Engl J Med"},{"issue":"13","key":"4792_CR37","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med 377(13):1228\u20131239","journal-title":"N Engl J Med"},{"key":"4792_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005379","author":"CL Roumie","year":"2017","unstructured":"Roumie CL, Min JY, D\u2019Agostino McGowan L et\u00a0al (2017) Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J\u00a0Am Heart Assoc. \n                    https:\/\/doi.org\/10.1161\/JAHA.116.005379","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"4792_CR39","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","volume":"5","author":"RR Holman","year":"2017","unstructured":"Holman RR, Coleman RL, Chan JCN et al (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5(11):877\u2013886","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"4792_CR40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"JL Chiasson","year":"2003","unstructured":"Chiasson JL, Josse RG, Gomis R et al (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4):486\u2013494","journal-title":"JAMA"},{"key":"4792_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.diabres.2017.12.011","volume":"136","author":"M Packer","year":"2018","unstructured":"Packer M (2018) Is metformin beneficial for heart failure in patients with type 2 diabetes? Diabetes Res Clin Pract 136:168\u2013170","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"4792_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/M16-1901","volume":"166","author":"MJ Crowley","year":"2017","unstructured":"Crowley MJ, Diamantidis CJ, McDuffie JR et\u00a0al (2017) Clinical outcomes of Metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166(3):191\u2013200","journal-title":"Ann Intern Med"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-019-4792-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:11:08Z","timestamp":1583453468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-019-4792-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4792"],"URL":"https:\/\/doi.org\/10.1007\/s00059-019-4792-9","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"7 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"K.\u00a0Sch\u00fctt declares the following: speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, OmniaMed; research grant from Boehringer Ingelheim; advisory board member of Amgen, Boehringer Ingelheim. N.\u00a0Marx declares the following: speaker fees from Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk, Bayer; research grant from Boehringer Ingelheim; advisory board member of Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, NovoNordisk. N.\u00a0Marx declines all personal compensation from pharmaceutical or medical device companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}